Stripe, Anthropic, the OpenAI Foundation, Flu Lab, Bill Gates, and several Jane Street Capital traders are collectively backing a new $500 million nonprofit called Intercept, with the stated goal of eliminating respiratory viruses, starting with the common cold and flu. The average person spends 5% of their lifetime sick with colds or flu. No major drug company has seriously tried to fix this, because over 200 different viruses cause the common cold alone, making any single vaccine commercially unviable.
Intercept was shaped by David Veesler, a structural biologist at the University of Washington who argued that broad-spectrum countermeasures are now technically feasible using RNA drugs, engineered antibodies, and computational protein design. One concrete idea: engineered proteins delivered as nasal sprays that physically trap viruses before infection begins. Intercept also plans to fund large-scale ultraviolet air-purification systems for schools and offices, treating airborne viruses the way municipal systems treat drinking water. Advisors include former FDA official Peter Marks and Moncef Slaoui, who led Operation Warp Speed.
The full piece is worth reading for the argument Veesler made to Stripe executive Nan Ransohoff, who calls it being 'nerd-sniped,' and for the comparison to Stripe's earlier $1.8 billion Frontier carbon removal program. The structural parallel, markets that won't self-correct without philanthropic intervention, is the organizing logic behind Intercept. NIAID spends $6.5 billion annually on virus research, but its budget has flatlined, and private capital is filling that gap in ways that set the research agenda.
[READ ORIGINAL →]